Nonstatin therapy for reduction of LDL-C
| Drug | Dose | Average LDL-C reduction |
|---|---|---|
| Ezetimibe | 10 mg, daily | 18% monotherapy 25% combined with statin |
| Alirocumab (Praluent) | 75 mg SC, every 2 weeks 150 mg SC, every 2 weeks | 45% 58% |
| Evolocumab (Repatha) | 140 mg SC, every 2 weeks 420 mg SC, every 4 weeks | 64% 58% |
LDL-C = low-density lipoprotein cholesterol; SC = subcutaneously